Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
Negredo
Eugenia
E
Ribalta
Josep
J
Ferré
Raimon
R
Salazar
Juliana
J
Rey-Joly
Celestino
C
Sirera
Guillem
G
Masana
Lluís
L
Clotet
Bonaventura
B
D000328:Adult; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D008076:Cholesterol, HDL / Q000097:blood*; D003521:Cyclopropanes; D016049:Didanosine / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D015999:Multivariate Analysis; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use
D000480:Alkynes; D048588:Benzoxazines; D008076:Cholesterol, HDL; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D008055:Lipids; D008074:Lipoproteins; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; C098320:efavirenz; D016049:Didanosine